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Etanercept is a soluble form of the tumor necrosis factor
receptor 2 (TNFR2) that inhibits pathological tumor necrosis
factor (TNF) responses in rheumatoid arthritis and other
inflammatory diseases. However, besides TNF, etanercept also
blocks lymphotoxin- (LT), which has no clear therapeutic
value and might aggravate some of the adverse effects associated
with etanercept. Poxviruses encode soluble TNFR2 homologs,
termed viral TNF decoy receptors (vTNFRs), that display unique
specificity properties. For instance, cytokine response modifier
D (CrmD) inhibits mouse and human TNF and mouse LT, but
it is inactive against human LT. Here, we analyzed the molec-
ular basis of these immunomodulatory activities in the ectrome-
lia virus– encoded CrmD. We found that the overall molecular
mechanism to bind TNF and LT from mouse and human origin
is fairly conserved in CrmD and dominated by a groove under its
50s loop. However, other ligand-specific binding determinants
optimize CrmD for the inhibition of mouse ligands, especially
mouse TNF. Moreover, we show that the inability of CrmD to
inhibit human LT is caused by a Glu-Phe-Glu motif in its 90s
loop. Importantly, transfer of this motif to etanercept dimin-
ished its anti-LT activity in >60-fold while weakening its TNF-
inhibitory capacity in 3-fold. This new etanercept variant could
potentially be used in the clinic as a safer alternative to conven-
tional etanercept. This work is the most detailed study of the
vTNFR–ligand interactions to date and illustrates that a better
knowledge of vTNFRs can provide valuable information to
improve current anti-TNF therapies.
The tumor necrosis factor superfamily (TNFSF)4 comprises
19 cytokines and 29 cellular receptors involved in essential bio-
logical processes such as cell death, immunity, and organ devel-
opment (1). However, a deregulated production of these cyto-
kines can provoke autoimmunity and inflammatory disorders.
For instance, Crohn’s disease, psoriasis, ankylosing spondylitis,
rheumatoid arthritis, and inflammatory bowel disease are often
associated with the uncontrolled activity of tumor necrosis fac-
tor  (TNF), the archetypical cytokine of the family (2). To date,
there are five TNF inhibitors approved by the Food and Drug
Administration for the treatment of these diseases: four mono-
clonal antibodies (infliximab, adalimumab, certolizumab, and
golimumab) and a soluble decoy receptor, etanercept (3). Etan-
ercept is a fusion protein of the ligand-binding domain of the
cellular TNF receptor 2 (TNFR2) with the Fc portion of a
human IgG1 (4). Importantly, despite its proven efficiency in
ameliorating patient symptomatology, etanercept can also
cause major adverse effects, including increased susceptibility
to infections, lymphoma, and heart failure (5). These side
effects might be explained, at least in part, by the fact that etan-
ercept blocks not only TNF but also other TNFSF ligands essen-
tial for homeostasis and immunity like lymphotoxin  (LT)
(6). Redesign of this molecule appears to be desirable for its
safer application in the clinic.
Poxviruses have evolved a similar strategy to inhibit TNFSF
ligands in their hosts. Members of the Orthopoxvirus genus
encode up to four different soluble viral TNF decoy receptors
(vTNFRs), termed cytokine response modifier B (CrmB),
CrmC, CrmD, and CrmE, that display differential ligand and
species specificity profiles (7). For instance, CrmC and CrmE
are specific mouse TNF (mTNF) and human TNF (hTNF)
inhibitors, respectively, whereas CrmB and CrmD inhibit TNF,
LT, and LT (8 –12). Furthermore, although CrmD, the only
active vTNFR encoded by the mouse-specific ectromelia virus
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(ECTV), is the vTNFR with the highest binding affinity for
mouse LT (mLT), it fails to neutralize human LT (hLT)
(12). In fact, CrmB, encoded by the human variola virus, is the
only vTNFR that blocks hLT (12). Thus, it appears that
vTNFRs have evolved to fulfill the particular immunomodula-
tory needs of poxviruses according to their host species. This
level of specialization to discriminate between mouse and
human cytokine counterparts or between the highly related
TNF and LT is rare among cellular TNFSF receptors (TNFRs)
(13). Therefore, understanding the molecular determinants of
the vTNFR–ligand interactions could reveal new molecular
strategies to improve the TNF specificity of etanercept and
increase its clinical safety.
To date, the uncomplexed form of CrmE is the only vTNFR
whose structure has been solved (14). This structure confirmed
that vTNFRs mimic the three-dimensional folding of the
ligand-binding moiety of cellular TNFRs, which is formed by a
variable number of cysteine-rich domain (CRD) pseudorepeats.
The folding of a typical CRD is maintained by three disulfide
bonds established by six highly conserved cysteines (15). Cellu-
lar TNFRs may comprise up to five CRDs (16). 15 of the 29
different TNFRs contain at least three CRDs. In most of these,
CRD2 and CRD3 constitute the principal ligand-binding sites
(17). In particular, two loops located in these two CRDs and
designated the 50s and the 90s loop, respectively, are known to
act as the dominant ligand-binding determinants in several
receptor–ligand complexes (18 –20). In contrast, the CRD1,
although usually not directly involved in ligand binding, can
mediate the self-association of some cellular TNFRs in a ligand-
independent manner, which has been proposed to enhance the
ligand-binding affinity and the signaling potency of the recep-
tor (21–23). For this reason, the CRD1 was termed preligand
assembly domain (PLAD).
However, little is known about how vTNFRs interact with
their ligands. T2, a CrmB homolog encoded by the Leporipox-
virus myxoma virus (MYXV), is the only vTNFR whose ligand-
binding site has been characterized to some extent. Analysis of
T2 truncated mutants showed that, like in many cellular
TNFRs, the CRD2 and CRD3 were essential for TNF binding
(24). However, the precise molecular bases of the vTNFR–
ligand interactions remain mostly unexplored. Interestingly, a
PLAD-like function has been attributed to the CRD1 of MYXV
T2. It was shown that T2 can interfere with TNF signaling in a
ligand-independent manner by interacting with the CRD1 of
TNFR1 or TNFR2 to generate unresponsive heterotrimers (25).
Conversely, the structure of CrmE did not confirm the exis-
tence of a PLAD in other vTNFRs (14), and whether the CRD1
can induce self-oligomerization in vTNFRs is not completely
understood. Furthermore, even the number of CRDs that con-
stitute the TNF-binding domain of vTNFRs remains controver-
sial, and precise allocation of the TNF-binding moiety in these
viral decoy receptors is still missing. This is especially impor-
tant in the case of CrmB and CrmD, whose TNF-binding
domain precedes an extended C-terminal domain absent from
CrmC and CrmE and named smallpox-encoded chemokine
receptor (SECRET) domain that binds and inhibits a limited
number of chemokines (26). We have recently demonstrated
that CrmD is an essential virulence factor for ECTV, which
causes mousepox, a smallpox-like disease in mouse. In addi-
tion, we showed that both CrmD activities, anti-TNF and anti-
chemokine, are required for a successful evasion of the host
immune response by ECTV (27).
Here, we precisely define the TNF-binding moiety of CrmD,
discuss the existence of a PLAD in this vTNFR, and provide new
insights into the molecular bases of its interaction with TNF
and LT of mouse and human origin. Importantly, we applied
the information extracted from our CrmD analysis to severely
curb the anti-LT activity of etanercept without dismantling its
TNF-inhibitory properties. This study offers molecular data
that might help to understand the role of each CrmD-inhibitory
activity in ECTV pathogenesis and provides proof of principle
that structural characterization of vTNFRs may be of great
value to improve current anti-TNF therapies.
Results
Fine mapping of the TNF- and chemokine-binding domains of
CrmD
The TNF-binding domain of CrmD is proposed to be formed
by four CRDs (10); however, the amino acids that mark the end
of the TNF-binding moiety and the beginning of the anti-
chemokine SECRET domain have never been experimentally
identified. Therefore, we first wanted to precisely delimit the
amino acid sequence that constitutes the TNF-binding domain
of CrmD.
We addressed this question indirectly by identifying the
beginning of the SECRET domain. Three chemokine-binding
proteins with sequence and functional similarities to the
SECRET domain have been characterized in poxviruses, named
SECRET-containing protein 1 (SCP1), SCP2, and SCP3 (26). As
shown in Fig. 1A, the amino acid sequences of these SCPs align
with that of the SECRET domain of CrmB and CrmD, a domain
missing from CrmC and CrmE. Interestingly, an FN motif
(Phe163 and Asn164) conserved at the N terminus of all SCPs is
also present in the putative CRD4 of CrmD and CrmB but
absent in CrmC and CrmE (Fig. 1A). This observation sug-
gested that Phe163 and Asn164 of CrmD could actually be
important for chemokine binding. To evaluate this, we com-
pared the chemokine-binding affinities of two CrmD truncated
mutants for two different forms of the SECRET domain:
SECRET163 (Phe163–Asp320), containing the Phe163 and
Asn164 conserved in the SCPs, and SECRET181 (Ser181–
Asp320), which includes the C-terminal sequence immediately
after the putative CRD4 of CrmD (Fig. 1B). These two SECRET
domain forms were expressed and purified by recombinant
baculoviruses alongside the full-length CrmD and CRD-CrmD
(Asp21–Ser162), a truncated CrmD mutant containing the
sequence immediately N-terminal to the sequence of the
SECRET163 protein (Fig. 1, B and C).
Using surface plasmon resonance (SPR), we calculated the
binding affinity constant (KD) of these four recombinant pro-
teins for the TNFSF ligands mTNF, hTNF, mLT, and hLT
and the mouse chemokines Ccl25, Ccl27, Cxcl11, Cxcl12, and
Cxcl13 (Fig. 2A). As expected, CRD-CrmD and the SECRET
domain proteins interacted exclusively with TNFSF ligands or
chemokines, respectively (Fig. 2A). As shown in Fig. 2B,
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whereas full-length CrmD bound both mTNF and Ccl25, CRD-
CrmD and SECRET163 interacted only with mTNF or Ccl25,
respectively. Importantly, SECRET163, but not SECRET181,
fully conserved the chemokine-binding affinities of the full-
length protein (Fig. 2A). For instance, although CrmD bound
Ccl25 and Ccl27 with a KD of 4.86 and 5.41 nM, the binding
affinities of SECRET181 for these chemokines were 54.70 and
288.0 nM, a 1-log and about 2-log KD increase, respectively (Fig.
2A). By contrast, SECRET163 maintained the binding affinities
of CrmD for these two chemokines (KD, 5.99 and 7.91 nM,
respectively; Fig. 2A). Complementarily, the binding affinities
of CRD-CrmD (KD, 0.21–12.41 nM) for TNFSF ligands were
similar to those of the full-length CrmD (KD, 0.10 –50.40 nM) in
all cases (Fig. 2A). These results indicated that the sequence
from the putative CRD4 included in SECRET163 is dispensable
for the binding of TNFSF ligands but required for high-affinity
chemokine interactions.
We then analyzed whether CRD-CrmD and SECRET163
also conserved the capacity of the full-length protein to inhibit
the bioactivity of TNF and chemokines, respectively. As shown
in Fig. 2C, SECRET163 inhibited the Ccl25-induced che-
motaxis of MOLT-4 cells to the same extent that CrmD did,
reducing cell migration nearly 50% when incubated with the
chemokine at a 2 M excess and almost neutralizing chemotaxis
Figure 1. Expression of full-length and truncated CrmD recombinant proteins. A, Clustal Omega alignment of the amino acid sequences of the vTNFRs
CPXV CrmE (gene K3R, strain elephantpox, UniProt/TrEMBL accession number Q9DJL2), CPXV CrmC (gene CPXV191, strain Brighton Red, UniProt/TrEMBL
accession number Q9YP87), ECTV CrmD (gene E6, strain Hampstead, UniProt/TrEMBL accession number O57300), and VARV CrmB (gene G2R, strain Bangla-
desh 1975, UniProt/TrEMBL accession number P34015) and the SCPs CPXV SCP-1 (gene CPXV218, strain Brighton Red, UniProt/TrEMBL accession number
Q8QMN0), CPXV SCP-2 (gene CPXV014, strain Brighton Red, UniProt/TrEMBL accession number Q8QN47), CPXV SCP-3 (gene CPXV201, strain Brighton Red,
UniProt/TrEMBL accession number Q8QMP4), ECTV SCP-2 (gene EVN012, strain Naval, UniProt/TrEMBL accession number A0A075IJA5), and ECTV SCP-3 (gene
EVN184, strain Naval, UniProt/TrEMBL accession number A0A075ILK3). The signal peptides were removed before the alignment. Numbers at the end of each
line indicate the amino acid position relative to the complete protein sequence. The sequences were split into two columns corresponding to the CrmD
TNF-binding and SECRET domains as labeled above each column. The sequences of each CRD in the TNF-binding domain of vTNFRs are indicated with
differently colored lines. Conserved cysteines residues are shown in black background. An FN motif conserved in the SCPs and in the CRD4 of VARV CrmB and
ECTV CrmD is highlighted in red. B, schematic representation of the CrmD truncated proteins expressed by recombinant baculoviruses. The CrmD protein
molecule is depicted in blue. The two domains of CrmD, “TNF-binding domain” and “SECRET,” are labeled above. Ellipses numbered from 1 to 4 represent the
different CRDs in the TNF-binding domain. Below the blue diagram, the sequences included in the different CrmD truncated proteins (SECRET163, SECRET181,
and CRD-CrmD) as well as in the full-length CrmD are represented as solid black arrows. Dashed lines represent the portion of CrmD excluded in each truncated
protein. Amino acid positions pertinent for these four recombinant proteins are numbered above the CrmD blue diagram. C, Coomassie Blue–stained gels
showing the analysis of 1 l of the final concentrated protein stocks (indicated above each gel line) by SDS-PAGE. Molecular mass is indicated in kDa.
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at a 10 M excess (Fig. 2C). As expected, CRD-CrmD did not
inhibit the cell migration induced by Ccl25 (Fig. 2C). In con-
trast, CRD-CrmD, but not SECRET163, protected L929 cells
from the cytotoxic effect of mTNF. A 10 M excess of both CrmD
and CRD-CrmD protected at least 50% of the cells against
mTNF (Fig. 2D). These results confirmed our conclusions
based on the binding assays and indicated that the second half
of the putative CRD4 is not involved in TNF binding but it is
most likely part of the SECRET domain.
Expression and purification of CrmD mutants
To study the molecular bases of the CrmD interaction with
TNFSF ligands, we performed alanine site-directed mutagene-
sis of its TNF-binding domain, which we had just delimited to
the sequence Asp21–Ser162. We generated 14 different full-
length CrmD mutants affecting residues throughout this
sequence, including some related to three structural features
known to be important for ligand binding in most TNFRs: the
PLAD and the 50s and 90s loops.
The CRD1 or PLAD mediates the oligomerization of TNFRs
prior to the interaction with the ligand (21). A similar activity
was reported for the CRD1 of MYXV T2 (25), suggesting that
the PLAD could be an activity extendable to the CRD1 of
vTNFRs. However, beyond the six canonical Cys residues, there
is no discernible conserved PLAD sequence across the CRD1 of
vTNFRs and TNFRs (Fig. 3A). TNFR1 K19A/Y20A and K32A
mutants are known to lose the self-association and ligand-bind-
ing abilities of the wildtype (WT) receptor (28). These residues
are somewhat conserved in CrmD (Fig. 3A). Therefore, to eval-
uate whether they play a similar role in vTNFRs, we generated
the CrmD mutants D35A/Y36A and K44A (Fig. 3A). Using size
exclusion chromatography and native gel electrophoresis, we
found that the oligomeric state of the protein was unaltered in
the CrmD D35A/Y36A mutant (Fig. S1), which argued against a
central role of these residues in the potential oligomerization of
CrmD.
The 50s loop in the CRD2 and the 90s loop in the CRD3 are
known to be essential ligand-binding determinants in most
TNFRs (18, 20, 29 –31). Initial binding models proposed that
conserved hydrophobic interactions in the 50s loop, critical for
the binding affinity, orient the ligand to favor polar interactions
by the 90s loop, which defines the ligand specificity (18). How-
Figure 2. SECRET163, but not SECRET181, displays chemokine-binding and -inhibitory activities comparable with those of full-length CrmD. A, TNFSF
ligand- and chemokine-binding affinity constants (KD) of the CrmD truncated mutants calculated by SPR. The table shows the mean  S.D. KD in nM units. nbd,
no binding detected; na, not assayed. B, SPR sensorgrams showing the binding of 100 nM mTNF or mouse Ccl25 to CM4 chips immobilized with CrmD (blue),
CRD-CrmD (red), or SECRET163 (green). Black arrows indicate the end of the analyte injection. C, MOLT-4 cell chemotaxis assay. MOLT-4 transwell migration was
induced by 70 nM mouse Ccl25 preincubated in the absence (Ccl25) or presence of recombinant protein at the indicated chemokine:protein molar ratios (see
legend) of CrmD, SECRET163, or CRD-CrmD. Migrated cells were detected using a Cell Titer Aqueous One Solution kit and measuring the A490 in a microplate
reader. Media indicates the cell migration detected in the absence of chemokines. Data are represented as the percentage of migration relative to the A490
detected when the cells were incubated with the chemokine alone (Ccl25). D, mTNF-induced cytotoxicity assay on L929 cells. L929 cells were incubated with
1.2 nM mTNF in the absence or presence of recombinant protein at increasing mTNF:protein molar ratios (see legend). Cell viability was assessed as the A490
determined using a Cell Titer Aqueous One Solution kit. The A490 calculated for cells incubated with mTNF alone (mTNF) was subtracted from all samples. Data
are represented as the percentage relative to the A490 recorded for cells incubated without mTNF (media). In C and D, results are shown as mean  S.D. (error
bars) of triplicates of one experiment representative of three independent experiments.
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ever, a significant number of other TNFSF ligand–receptor
complexes are known to diverge from this general model (19,
20, 30, 32, 33). Therefore, the precise ligand-binding determi-
nants of TNFRs can be very variable and difficult to predict
solely from structural models. In fact, even the application of
receptor-based molecular replacement has proved to be prob-
lematic for the structural determination of some TNFR–ligand
complexes (34). In this situation, we selected our CrmD alanine
mutants (targeted residues highlighted in red in Fig. 3A) based
on its alignment with other vTNFRs and its more highly related
cellular counterparts, TNFR1 and TNFR2 (Fig. 3A). We
mutated residues unique to CrmD as well as conserved amino
acids either within the 50s and 90s loops or in other regions of
the CRD2 and CRD3 (Fig. 3A). To guarantee that at least one of
our mutants lost all ligand-binding capabilities, besides its cor-
responding alanine mutation, we generated CrmD N77F,
equivalent to a reported TNFR1 N66F mutant known to be
unable to interact with TNF (21).
All 14 CrmD mutants were expressed by recombinant bacu-
loviruses and purified from supernatants of infected insect cells
(Fig. 3B). To rule out the possibility that the introduced muta-
tions drastically affected the overall CrmD three-dimensional
folding, we tested the ability of the mutants to inhibit Ccl25-
induced chemotaxis. As shown in Fig. 3C, the chemokine-in-
hibitory activity of the WT protein was preserved in all
mutants.
Conserved and ligand-specific molecular bases drive the
interaction of CrmD with TNF and LT of mouse and human
origin
To define the implication of the mutated residues in the
CrmD ligand-binding mechanism, we determined the binding
affinity of all mutants for four different CrmD ligands, mTNF,
hTNF, mLT, and hLT, by SPR (Table 1). Fig. 4A shows some
examples of the sensorgram fittings performed to calculate the
binding affinity and kinetic constants presented in Table 1.
Those cases in which no binding was detected or the binding
was so weak that it did not allow a reliable determination of the
affinity constants within the system detection limits are indi-
cated as nbd for “no binding detected” (Table 1 and Fig. 4B). Fig.
4B summarizes the -fold change caused by each mutation on
the corresponding ligand binding KD of the WT protein. Fig. 4C
shows the position in the surface of a CrmD structural model of
those residues that when mutated resulted in a significant mod-
ification of the protein KD for each ligand. CrmD N77F was not
able to interact with any cytokine (Table 1 and Fig. 4B); how-
Figure 3. CrmD site-directed mutagenesis. A, Clustal Omega alignment of the amino acid sequences of the first three CRDs of the vTNFRs CPXV CrmE (gene
K3R, strain elephantpox, UniProt/TrEMBL accession number Q9DJL2), CPXV CrmC (gene CPXV191, strain Brighton Red, UniProt/TrEMBL accession number
Q9YP87), ECTV CrmD (gene E6, strain Hampstead, UniProt/TrEMBL accession number 057300), VARV CrmB (gene G2R, strain Bangladesh 1975, UniProt/TrEMBL
accession number P34015), and MYXV T2 (gene m002L, strain MAV, UniProt/TrEMBL accession number E2CZP3) and the human TNFRs TNFRl (gene TNFRSFlA,
UniProt/TrEMBL accession number P19438) and TNFR2 (gene TNFRSFlB, UniProt/TrEMBL accession number P20333). CrmD residues subjected to mutagenesis
are highlighted in red. Sequences corresponding to the 50s and 90s loops are framed in red and labeled accordingly above the frame. Conserved cysteines are
shown in a black background. Numbers at the end of each line indicate the amino acid position of the last residue in the line relative to the complete sequence
of the protein. B, Coomassie Blue–stained gel showing the SDS-PAGE analysis of 1 l of the protein stock purified for each mutant. Molecular mass is shown in
kDa. C, inhibition of mouse Ccl25-induced chemotaxis of MOLT-4 cells by CrmD WT or the indicated mutants. 70 nM chemokine was preincubated in the
absence or presence of recombinant protein at increasing chemokine:protein molar ratios (see legend), and its ability to induce transwell migration of MOLT-4
cells was assessed. Migrated cells were detected by measuring the A490 using a Cell Titer Aqueous One Solution kit. Data are represented as the percentage
relative to the A490 detected when the cells were incubated with the chemokine alone (Cc125). Media indicates the cell migration recorded in the absence of
chemokine. Results are shown as mean  S.D. (error bars) of triplicates from one experiment representative of three independent experiments.
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ever, only the alanine mutation of this residue was considered
for the construction of Fig. 4C.
Some similarities were found in the molecular bases that
drive the interaction of CrmD with mTNF, hTNF, mLT,
and hLT. In particular, certain residues in the CRD1 (Asp35
and Tyr36), CRD2 (Phe72, Thr73, Ser74, Gln103, and Asp104), and
CRD3 (Asp146 and Ile148), although to a different extent in some
cases, were consistently important for the CrmD interaction
with all four ligands (Fig. 4, B and C). The most evident of these
common binding determinants was a groove in the CRD2 (Fig.
4C). Mutation of Phe72, Thr73, Ser74, Gln103, and Asp104,
located in a CRD2 groove formed under the 50s loop, abolished
all ligand-binding abilities of CrmD (Fig. 4, B and C). Similarly,
mutation of two residues of the distal CRD3, Asp146 and Ile148,
consistently reduced the binding affinity for all ligands (8.9-,
3.6-, 3.3-, and 5.4-fold KD increases for mTNF, hTNF, mLT,
and hLT, respectively) (Fig. 4B). In addition, mutation of three
other amino acids in the C-terminal region of CRD3, Tyr141,
Ser142, and Ser143, also decreased the CrmD-binding affinity for
mTNF (8.6-fold), hTNF (5.4-fold), and mLT (11.9-fold) but
not for hLT (Fig. 4B). These results indicated that this C-ter-
minal region of the CRD3 is important for the ligand-binding
properties of CrmD. Finally, we found that mutation of Asp35
and Tyr36 in the CRD1 significantly increased the KD for all
ligands, with a more markedly deleterious effect on mTNF
(17.3-fold KD increase) than on hTNF or mLT binding (5.3-
and 3.7-fold KD increase, respectively) (Fig. 4B). Surprisingly,
we did not detect hLT binding by this D35A/Y36A mutant
(Table 1 and Fig. 4, A and B); however, it is important to note
that due to cytokine supply limitations, 1 M was the highest
ligand concentration included in our experiments. In these
conditions, given the lower binding affinity of CrmD for hLT
(KD, 50.40 nM), 20-fold was the highest KD increase detectable
for this ligand. The same applies to the mutant Q93A/E95A,
which did not bind hLT but conserved the hTNF- and mLT-
binding affinity of the WT protein and displayed a 9-fold
increase in the mTNF KD (Fig. 4B).
We also identified several ligand-specific differences among
our CrmD mutants. First, interestingly, the KD for mTNF was
increased in many more mutants than for any other cytokine
(Fig. 4B). Besides the conserved binding determinants men-
tioned above, mutation of amino acid residues located in the
50s loop (His78 and Ser79), the 90s loop (Glu116, Phe117, and
Glu118), and the connecting region between these loops (Arg86,
Lys88, Ser90, Ser91, Gln93, and Glu95) reduced the mTNF-bind-
ing affinity without significantly damaging the binding of other
ligands (Fig. 4B). This suggests that CrmD might establish a
closer contact to mTNF with more residues involved in the
interaction. Interestingly, many of these mTNF-specific bind-
ing determinants appeared to obstruct the hLT binding by
CrmD. For instance, mutation of His78 and Ser79 or Arg86 and
Lys88 increased the hLT-binding affinity 4.3- and a 3.7-fold,
respectively (Fig. 4B). More strikingly, an E116A/F117A/E118A
mutant displayed a remarkable 22.7-fold surge in the hLT-
binding affinity (Fig. 4, A–C, and Table 1).
We concluded that the core of the molecular mechanism of
CrmD binding to mTNF, hTNF, mLT, and hLT is formed by
essentially the same group of amino acids. However, consistent
with the fact that CrmD is expressed by ECTV, a strictly mouse
pathogen, additional residues appear to have specialized CrmD
for the interaction with mTNF at the cost of weakening its
interaction with hLT, a biologically irrelevant cytokine for a
virus that does not infect humans.
Inhibition of TNFSF cytokines by CrmD mutants
Although vTNFRs usually neutralize their ligands, there are
examples of noninhibitory vTNFR–ligand high-affinity inter-
actions. For instance, CrmE binds both mTNF and hTNF with
a binding affinity below the nanomolar range but only blocks
hTNF (12). This suggests that the ligand-binding and -neutral-
izing determinants may differ in vTNFRs. Therefore, to com-
plete our understanding of the CrmD biochemistry, we ana-
lyzed the ability of each mutant to inhibit the cytotoxic activity
of mTNF, hTNF, mLT, and hLT on L929 cells.
As shown in Fig. 5, in the absence of inhibitors, mTNF,
hTNF, mLT, and hLT were cytotoxic and killed the cells (Fig.
5, Cytokine). However, in the presence of recombinant protein
(Fig. 5, CrmD WT or mutant), added at the indicated cytokine:
protein molar ratios, different cell survival rates were recorded.
As expected, those mutants with no ligand-binding capacity,
Table 1
Kinetic affinity constants of the mTNF, hTNF, mLT, and hLT binding by CrmD mutants
CrmD genotype variants are shown in the left column. The association constant (Ka), dissociation constant (Kd), and their respective standard errors (S.E.) for each cytokine
are indicated. The binding affinity constant (KD, in bold) is shown in nM units. nbd, no binding detected.
CrmD
mTNF hTNF mLT hLT
Ka  S.E.a Kd  S.E.b KD Ka  S.E. Kd  S.E. KD Ka  S.E. Kd  S.E. KD Ka  S.E. Kd  S.E. KD
WT 3.27  0.02 0.33  0.07 0.10 9.64  0.03 3.94  0.09 0.41 2.31  0.01 9.86  0.11 4.27 0.60  0.01 30.10  0.27 50.40
D35A/Y36A 3.75  0.02 6.50  0.70 1.73 20.80  0.31 45.00  2.20 2.16 2.72  0.04 43.30  1.09 15.90 nbd nbd nbd
K44A 2.81  0.01 0.29  0.07 0.10 8.49  0.03 3.24  0.11 0.40 1.20  0.02 5.93  0.22 4.95 0.40  0.01 30.40  0.26 75.80
P68A 4.07  0.01 0.61  0.06 0.15 11.10  0.03 2.90  0.08 0.26 2.66  0.03 12.60  0.34 4.71 1.22  0.01 23.60  0.24 19.30
F72A/T73A/S74A nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd
N77A 4.75  0.02 2.59  0.11 0.55 15.60  0.26 45.90  1.33 2.47 0.22  0.03 13.90  0.61 62.00 5.56  0.20 411.00  8.39 73.90
N77F nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd
H78A/S79A 2.97  0.03 2.39  0.33 0.80 16.10  0.06 8.19  0.16 0.51 3.00  0.04 6.12  0.10 2.04 4.81  0.07 55.80  0.68 11.60
R86A/K88A 3.13  0.02 2.30  0.45 0.73 11.60  0.04 6.28  0.10 0.54 0.84  0.01 6.19  0.21 7.02 6.09  0.11 82.50  0.82 13.50
S90A/S91A 2.34  0.01 2.36  0.06 1.00 15.90  0.08 11.10  0.16 0.70 1.25  0.01 8.58  0.14 6.99 0.49  0.01 20.10  0.31 41.10
Q93A/E95A 3.19  0.01 2.87  0.11 0.90 15.40  0.10 17.00  0.22 1.11 2.84  0.03 32.00  0.64 11.20 nbd nbd nbd
Q103A/D104A/R105A nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd nbd
E116A/F117A/E118A 2.29  0.01 1.93  0.64 0.84 10.70  0.09 12.50  1.35 1.17 2.38  0.03 13.30  0.22 5.58 5.08  0.02 11.30  0.09 2.22
Y141A/S142A/S143A 3.05  0.03 2.62  0.10 0.86 14.70  0.12 32.70  0.96 2.23 0.41  0.01 20.70  0.28 50.60 0.30  0.01 50.70  0.99 107.00
D146A/I148A 4.91  0.03 4.35  0.45 0.89 21.20  0.22 31.00  1.28 1.46 3.22  0.05 46.00  1.51 14.30 1.15  0.04 312.00  8.15 271.00
a Ka  S.E.  105 (1/M s).
b Kd  S.E.  104 (1/s).
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the N77F control mutant and the CRD2 groove mutants F72A/
T73A/S74A and Q103A/D104A/R105A, failed to protect the
cells from the activity of any of the four cytokines tested (Fig. 5).
Therefore, we concluded that the CRD2 groove is critical not
only for the binding but also for the inhibitory properties of
CrmD.
An evident ligand-specific effect was not detected among the
other CrmD mutants. Mutations that impaired to some extent
the capacity of CrmD to inhibit mTNF also affected to different
degrees the anti-hTNF and anti-mLT activity of the protein
(Fig. 5). This suggests that CrmD deploys a similar molecular
mechanism to inhibit these three cytokines. However, interest-
ingly, the anti-hTNF effect of CrmD was more markedly sus-
ceptible to mutagenesis than its ability to block the mouse cyto-
kines, which may suggest a more robust design to target murine
ligands. For instance, low doses of CrmD WT (1:20) were suf-
ficient to cause nearly 100% cell survival in both mTNF- and
hTNF-mediated cytotoxicity assays (Fig. 5). However, at this
same dose, the mutants D35A/Y36A, N77A, Q93A/E95A, and
D146A/I148A were inactive against hTNF, whereas they pro-
Figure 4. Effect of the CrmD mutants on ligand-binding affinity. The binding affinity of the CrmD mutants for mTNF, hTNF, mLT, and hLT was calculated
by SPR. A, examples of the binding sensorgrams and fittings obtained for the determination of the binding kinetic constants shown in Table 1. The correspond-
ing analyte and CrmD mutant are indicated above each graph column and at the top right corner of each graph, respectively. The top graph row includes
sensorgrams for CrmD mutants whose binding affinity for the indicated cytokine was comparable with that of WT CrmD. The middle row contains sensorgrams
for mutants with significantly reduced (Y141A/S142A/S143A:mTNF, D35A/Y36A:hTNF, and N77A:mLT) or enhanced (E116A/F117A/E118A:hLT) binding
affinity, and the bottom row shows examples where no binding was detected (nbd) or it was too weak to be analyzed accurately. B, -fold change (KD(mutant)/
KD(WT)) caused by each CrmD mutant on the KD of CrmD WT for mTNF, hTNF, mLT, and hLT. The KD -fold change range that was considered nonsignificant
(0.3–3) is shaded in gray. nbd, no binding detected. In C, residues whose alanine mutation resulted in a significant increase (3-fold change) or decrease
(0.3-fold change) in the KD of CrmD WT for each ligand are located, colored, and labeled on a model of the CrmD surface (gray) generated by I-TASSER (62).
The corresponding ligands are shown above the CrmD models. The legend indicates the colors assigned to the different KD -fold change ranges. The maximum
detectable KD -fold increase (red) varied among the different analytes (20 for hLT, 200 for mLT, and 2,000 for mTNF and hTNF).
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tected at least 50% of the cells from mTNF (Fig. 5). Further-
more, the mutant Y141A/S142A/S143A showed no signs of
hTNF-inhibitory capacity, whereas it protected 25 and 75% of
the cells from mTNF and mLT at the low and high protein
dose, respectively. Most of these mutations that impaired the
CrmD-inhibitory properties also displayed a reduced binding
affinity for the corresponding cytokine. However, this was not
always the case. For instance, the anti-mTNF activity of H78A/
S79A, R86A/K88A, and S90A/S91A, despite their significant
loss of mTNF-binding affinity (Table 1 and Fig. 4B), was indis-
tinguishable from that of CrmD WT. Therefore, these residues
contribute to the binding but are dispensable for the neutral-
ization of mTNF by CrmD.
Consistent with the lower binding affinity of CrmD for hLT
(KD, 50.40 nM; Table 1) and as reported previously (12), CrmD
failed to inhibit this cytokine. Even in the presence of a 100 M
excess of CrmD WT, hLT killed 100% of the L929 cells (Fig. 5).
This hindered our ability in this assay to study the functional
effects of those mutations that reduced the CrmD-binding
affinity for hLT. However, we found that the CrmD mutant
E116A/F117A/E118A displayed a remarkable gain of anti-
hLT activity, reaching full cellular protection at the higher
dose tested (Fig. 5). This was consistent with the high hLT-
binding affinity of this mutant (KD, 2.22 nM; Table 1). This
result indicates that CrmD is perfectly equipped to inhibit
hLT, but an EFE motif in its 90s loop, although innocuous for
the capacity of the protein to block mTNF, hTNF, and mLT,
keeps it inactive against hLT.
Transfer of the EFE motif of CrmD into the 90s loop of
etanercept specifically impairs its anti-hLT activity
The inflammatory diseases currently treated with etaner-
cept are predominantly TNF-driven. Therefore, the anti-
hLT activity of etanercept not only appears to be clinically
unnecessary, but it could also pose a source of unwanted com-
plications. Having shown that a 90s loop EFE motif in CrmD
specifically hinders its anti-hLT activity, we hypothesized
that, by transferring the EFE motif of CrmD into the 90s loop of
etanercept, we could disrupt its anti-hLT activity while keep-
ing it active against hTNF.
The amino acid sequence alignment in Fig. 3A shows that the
EFE motif (Glu116-Phe117-Glu118) in the CRD3 of CrmD aligns
with an ALS motif (Ala127-Leu128-Ser129) in the 90s loop of
human TNFR2, which corresponds to the TNF-binding moiety
of etanercept. Furthermore, we observed that in the crystal
structure of the TNFR2–TNF complex (Protein Data Bank
(PDB) code 3ALQ) the TNFR2 Ser129 was not facing the ligand
(Fig. 6A). Similarly, the structural superimposition of a CrmD
model with the structure of TNFR2 suggested that the third
amino acid of this motif in CrmD, Glu118, would also be far from
the ligand interface. Thus, to introduce the lowest number of
modifications into the original sequence of etanercept, we
mutated only the TNFR2 Ala127 and Leu128 to their equivalent
amino acids in the 90s loop of CrmD (Glu and Phe). We gener-
ated recombinant baculoviruses for the expression of the dou-
ble mutant A127E/L128F and the two single mutants A127E
and L128F. Unfortunately, for unknown reasons, we were not
able to successfully express the A127E protein in this system.
SPR analysis revealed that the hTNF- and hLT-binding affin-
ities of etanercept were not significantly affected in the mutants
(Fig. 6B). However, as we have discussed above, binding affinity
does not always correlate with neutralizing potency. Therefore,
we compared the capacity of L128F, A127E/L128F, and WT
etanercept to block the cytotoxic activity of hTNF and hLT on
L929 cells. As shown in Fig. 6C, 20 nM etanercept WT was
enough to fully neutralize both hTNF and hLT (Fig. 6C),
reaching 50% cell viability at 10 –20 and 5 nM (EC50), respec-
Figure 5. Inhibitory properties of CrmD mutants. A cytotoxic dose of mTNF, hTNF, mLT, and hLT was incubated with L929 cells in the absence (Cytokine)
or presence of CrmD WT or the indicated mutants at increasing cytokine:protein molar ratios (see legends above each graph). After 18 h, cell survival was
assessed as the A490 determined using a Cell Titer Aqueous One Solution kit. Data are represented as the percentage relative to the A490 recorded for cells
incubated without cytokine (Media; 100% cell viability). The corresponding effector cytokine is indicated above each graph. Results are shown as mean  S.D.
(error bars) of triplicates of three representative experiments. Asterisks indicate mutants that displayed significantly different viability values compared with
CrmD WT at the same protein dose (*, p  0.05, analysis of variance with Bonferroni multiple comparison test).
An etanercept mutant lacking anti-hLT activity
J. Biol. Chem. (2019) 294(13) 5214 –5227 5221
tively. The L128F mutant was functionally indistinguishable
from WT etanercept (Fig. 6C). In contrast, the A127E/L128F
etanercept protected 50% of the cells from hTNF at 30 – 60 nM
and reached full protection at 90 nM (Fig. 6C). However, this
double mutant showed a very low anti-hLT activity and
required a high 300 nM dose to protect only 35% of the cells
from this cytokine (Fig. 6C), positioning its anti-hLT EC50 at
even higher concentrations. Therefore, although the anti-
hTNF activity of etanercept was reduced by 3 in the A127E/
L128F mutant, this variant was at least a 60 weaker hLT
inhibitor. These results confirmed our observations in CrmD
and indicated that the 90s loop of viral and cellular TNFRs may
contain important molecular determinants for the LT species
specificity.
Discussion
Multiple efforts have been made to characterize the immu-
nomodulatory capacities of vTNFRs in vivo and in vitro; how-
ever, the molecular mechanisms of vTNFR–ligand interactions
remain poorly analyzed. This work contributes to this gap of
knowledge by delineating the molecular bases of the CrmD
interaction with TNF and LT. In addition, we present the first
empirical evidence for the CrmD TNF-binding domain bound-
aries. More importantly, our work proves that structural anal-
yses of vTNFRs can be of great value to improve anti-TNF ther-
apies based on soluble decoy receptors.
There is no consensus yet about the number of CRDs that
constitute the TNF-binding domain of vTNFRs. For instance,
CrmC and CrmE have been indistinctly represented in the lit-
erature with either four or three CRDs (9, 11, 14, 26, 35, 36). It is
assumed that CrmD and CrmB consist of an N-terminal
four-CRD TNF-binding domain and a C-terminal SECRET
domain (10, 26). However, we have demonstrated here that
the second half of the CRD4, beginning at an FN motif con-
served in all SECRET-containing proteins, although dispens-
able for the CrmD anti-TNF activity, is essential for the high-
affinity chemokine interactions by the SECRET domain.
Consistent with this, the C-terminal region of the CRD4 of
CrmD and CrmB contains two amino acids, Asp167 and
Glu169 (Fig. 1A), that were identified as key chemokine-bind-
ing determinants in the structure of the SECRET–CX3CL1
complex (37). Therefore, we concluded that Phe163 and the
sequence at its C terminus belong to the SECRET domain. In
which domain the first half of the CRD4 should be allocated
remains to be elucidated. A previous analysis of T2 truncated
mutants showed that the CRD4 was dispensable for the anti-
TNF activity of this CrmB homolog (38). Therefore, the ves-
tigial CRD4 of orthopoxvirus-encoded vTNFRs is unlikely to
contribute to TNF binding. The function of the CRD4 in
cellular TNFR1 and TNFR2 remains unclear. Its proximity to
the cell membrane suggests that the CRD4 may facilitate the
surface exposition of the ligand-binding domain and the
transition to the intracellular signaling domain. This would
explain why a complete CRD4 is unnecessary in soluble
vTNFRs.
Figure 6. Etanercept A127E/L128F mutant displays enhanced TNF-neutralizing specificity. A, localization of the side chains of the EFE motif in the
90s loop of CrmD. CrmD three-dimensional folding was modeled using I-TASSER and aligned with the crystallographic structure of the TNFR2–TNF
structure (PDB code 3ALQ) in Chimera. CrmD and TNFR2 are represented as yellow and blue ribbons, respectively. The surface of the human TNF trimer
is shown in gray. Bottom panel, magnification of the 90s loop region (dashed frame) showing the side chains of the overlapping EFE and ALS motifs
of CrmD and TNFR2, respectively. B, hTNF- and hLT-binding affinity of WT, L128F, and A127E/L128F etanercept calculated by SPR. The kinetic affinity
constants, association (Ka), dissociation (Kd), and binding affinity (KD), and their S.E. are shown for each interaction. C, hTNF- and hLT-mediated
cytotoxicity assays. L929 cells were incubated with 1a .2 nM concentration of the corresponding cytokine, as labeled above each graph, with increasing
concentrations of WT (black circles), L128F (white triangles), or A127E/Ll28F etanercept (white squares). After 18 h, cell viability was assessed as the A490
detected using a Cell Titer Aqueous One Solution kit. Data are represented as the percentage relative to the A490 recorded for cells incubated without
cytokine (100% cell viability). Means  S.D. (error bars) of triplicates from two independent experiments are shown. The horizontal line above the hTNF
graph indicates the etanercept concentrations in which statistically significant differences were detected between the anti-hTNF activity of the WT and
the A127E/L128F mutant (*, p  0.05, two-tailed t test).
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Like the CRD4, the CRD1 is rarely directly involved in ligand
binding. However, it has been shown that the CRD1 or PLAD
mediates the ligand-independent oligomerization of some
TNFRs, including TNFR1, TNFR2, CD40, Fas, and TRAIL
receptors (21, 22, 39 – 41). Whether the CRD1 may also induce
self-assembly in vTNFRs remains unclear. It has been reported
that the mutations K19A/Y20A and K32A disrupt the PLAD
activity of TNFR1, resulting in mutant receptors unable to oli-
gomerize and interact with TNF (21). In contrast, here we have
shown that equivalent mutations in CrmD, D35A/Y36A and
K44A, were only partially detrimental or completely innocu-
ous, respectively, for the activity of this vTNFR. In addition, we
confirmed that the protein oligomeric state was not altered in
the D35A/Y36A mutant. This suggests either that a PLAD is
missing from CrmD or that the molecular bases of a potential
PLAD in CrmD differ from those of the TNFR1 PLAD. Of note,
the CrmE crystallographic structure did not confirm the pres-
ence of a PLAD in this vTNFR (14). Interestingly, the authors
showed that CrmE Tyr28, equivalent to CrmD Tyr36, estab-
lished hydrophobic interactions with the 50s loop that might
contribute to the correct folding of this important ligand-bind-
ing site. This is consistent with molecular dynamics analysis of
TNFR1 that proposed that the CRD1 is essential to stabilize the
CRD2 conformation (42), suggesting that the ligand-binding
defects observed in TNFR PLAD mutants might be caused by a
subtle destabilization of the CRD2. The same might explain the
partial loss of activity in the CrmD D35A/Y36A mutant; how-
ever, a direct implication of these residues in ligand binding
cannot be excluded, especially because equivalent amino acids
were involved in the formation of the OX40 –OX40L complex
(32). It is important to mention that none of this invalidates the
possibility that vTNFRs may interfere with cellular TNFR sig-
naling by engaging receptor monomers through their CRD1 as
demonstrated for MYXV T2 (25). It would be interesting to
study whether CrmD can also impede the formation of active
TNFR oligomers and whether the CrmD D35A/Y36A mutant
lacks this activity.
An efficient soluble decoy receptor must interact with the
target cytokine but, more importantly, mask those residues of
the ligand involved in the binding to the cognate cellular recep-
tor. This might explain the lack of correlation that we observed
between the binding and neutralizing activity of some mutants.
CrmD residues contacting ligand amino acids not required for
the interaction with the cellular receptor may contribute to the
binding affinity but be irrelevant for the neutralizing activity
of CrmD. Conversely, mutations of CrmD residues blocking
key receptor-binding determinants of the ligand should be
expected to be the most detrimental. In this regard, we have
shown that mutations in a CRD2 groove under the 50s loop
stripped CrmD of all its anti-TNFSF properties. This is consis-
tent with the critical role assigned to this region in other TNFRs
(18, 20, 22, 29) where it is known to constitute a critical binding
site for a hydrophobic patch of the ligand where a highly con-
served tyrosine residue is the major binding determinant (16).
Mutation of this tyrosine is sufficient to abolish or seriously
damage the receptor-binding capacity of many TNFSF ligands,
including TNF, LT, FasL, TRAIL, TL1A, and LIGHT (43–48).
Therefore, this tyrosine should be a main target for any inhibi-
tor of these cytokines. The severe deleterious effect of muta-
tions in the CrmD CRD2 groove and the fact that all four
ligands analyzed here conserve this important tyrosine (mTNF,
Tyr165; hTNF, Tyr163; mLT, Tyr139; hLT, Tyr142) suggest
that this is the case for CrmD. This may also explain the inca-
pacity of CrmD N77F to bind and neutralize these cytokines.
The addition of a large aromatic residue at the rim of the CRD2
groove may constitute a steric hindrance that prevents a com-
petent fitting of the ligand’s tyrosine. It is important to note that
at present we cannot prove whether these inactive CrmD
mutants were properly folded. However, their high expression
yield and efficient secretion and the facts that their antichemo-
kine activity was intact and that the localization of these muta-
tions agrees with that of important ligand-binding determi-
nants in many other receptors suggest that this is likely to be the
case.
Despite the common binding mechanism deployed by the
CRD2 of many TNFRs, these receptors are very ligand-specific.
The determinants for this specificity appear to reside mostly in
the CRD3, which binds to more highly variable secondary
structural features of the ligand (31). The CRD3-mediated
interactions are essential for the stability of the receptor–ligand
complex. For instance, a Fas chimera carrying the CRD3 of
TNFR1 failed to interact with FasL (49), and a T2 truncated
mutant containing only the first two CRDs was unable to bind
TNF (38). Here, we have shown that several residues at the C
terminus of the CRD3 of CrmD significantly contribute to the
binding and inhibitory activity of this vTNFR. Of note, these
amino acids are located outside of the 90s loop at the C termi-
nus of the CRD3 of CrmD, a region rarely implicated in ligand
binding in cellular TNFRs, which might hint at a different bind-
ing mechanism by vTNFRs. More importantly, we proved that
an EFE motif at the 90s loop of the CRD3 prevents the anti-
hLT activity of CrmD, whereas it does not affect its interaction
with mLT. In contrast, the 90s loop of the effective hLT
inhibitors CrmB and etanercept contains nonaromatic and less
negatively charged motifs (LLK and ALS, respectively). To our
knowledge, this is the first evidence that the CRD3 may contain
not only ligand but also species specificity determinants.
Etanercept is the only Food and Drug Administration–
approved antirheumatic drug that blocks not only TNF but also
LT. Although it has been proposed that this double inhibitory
activity of etanercept could be beneficial in some instances (50),
the role of LT in inflammatory joint diseases is not well
defined. Furthermore, a rheumatoid arthritis clinical trial con-
cluded that an LT-neutralizing antibody, pateclizumab, was
not clinically different from placebo (51). On the contrary, sev-
eral reports have shown that LT is important for host defense
against Mycobacterium infections (52–54), which constitutes
one of the major infectious concerns in patients under anti-
TNF therapy (55). Importantly, the LT activity is more mark-
edly decisive in these infections in the absence of TNF (56, 57),
which simulates the undergoing immunological condition in
these patients. Therefore, although the systemic blockade of
TNF, a central cytokine of the immune response, is probably
largely responsible for the infection vulnerability observed in
etanercept patients, the anti-LT activity of this drug may only
contribute to aggravate the infections. A more specific anti-
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TNF treatment can be achieved with any of the four approved
TNF monoclonal antibodies. However, it has been reported
that the risk of infection associated with these antibodies can be
even higher than with etanercept (58). This might be explained
by the potent cytotoxic activity, complement-dependent cyto-
toxicity or antibody-dependent cellular cytotoxicity, mediated
by the Fc region of these antibodies, which may result in the
destruction of TNF-bearing immune cells (6, 59). This cytotox-
icity is diminished or missing in etanercept due to a structural
defect in its Fc region (6). Furthermore, etanercept is known
to be minimally immunogenic, whereas patients frequently
develop neutralizing antibodies against infliximab and adali-
mumab (60). All this together suggests that a TNF-specific
etanercept would be the ideal antirheumatic drug. Here, we
demonstrate that the anti-hLT activity of etanercept can be
vastly hampered by making its 90s loop look more like that of
CrmD in a A127E/L128F etanercept mutant. The slight defect
observed in the anti-hTNF activity of this mutant could poten-
tially be overcome in the clinic by a small dose increase without
compromising hLT-mediated immune functions. Therefore,
this A127E/L128F variant could set the foundation for a safer
second generation of etanercept featuring the benefits of a sol-
uble decoy receptor and the high TNF specificity of the anti-
body therapy.
In conclusion, with the few exceptions discussed above, our
results indicate that CrmD uses a similar molecular mechanism
to bind and block TNF and LT. This complicates the genera-
tion of recombinant ECTV expressing CrmD mutants active
only against one of its TNFSF ligands, which would be invalu-
able tools to dissect the functions of these cytokines in the anti-
poxvirus response. More detailed structural analyses of CrmD–
TNF and CrmD–LT complexes may reveal ligand-specific
binding determinants not detected here. However, we have
already proved this mutagenesis study useful for the generation
of a single point ECTV mutant incapable of blocking mTNF and
mLT (27). More importantly, we demonstrated here that
vTNFRs can provide a new perspective on TNFSF ligand-bind-
ing mechanisms and uncover novel specificity and binding
determinants that would be overlooked in studies limited to
cellular TNFRs. Given the strikingly different ligand-binding
and specificity profiles across vTNFRs, structural studies on
each of these viral decoy receptors have the potential to reveal
new molecular determinants for a more potent and specific
anti-TNF activity, which would refine our ability to neutralize
harmful TNF responses in the clinic.
Experimental procedures
Cells and reagents
L929 (ATCC, Manassas, VA) were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% FCS.
MOLT-4 cells (ATCC) were cultured in RPMI 1640 medium
supplemented with 10% FCS. Recombinant baculoviruses were
generated and amplified in adherent Hi5 insect cells cultured in
TC-100 medium supplemented with 10% FCS and 1 nones-
sential amino acids. Suspension Hi5 cells maintained in Express
Five (Life Technologies) medium supplemented with 8 mM
L-glutamine were used for the expression of recombinant pro-
tein. Recombinant cytokines were purchased from R&D Sys-
tems (Minneapolis, MN) and reconstituted and stored follow-
ing the manufacturer’s recommendations.
Construction of recombinant baculovirus
All the proteins described in this study were expressed by
recombinant baculoviruses. The ECTV strain Hampstead
CrmD coding sequence was extracted by PCR from a pBAC1
(Life Technologies)-derived plasmid termed pMS1 (11) using
the primers Crm34 (5-gcgggatccgatgttccgtatacacccattaatggg-
3) and CrmD33 (5-gcgctcgaggcatctctttcacaatcatttgg-3),
which contained a BamHI and a XhoI restriction site, respec-
tively. These primers amplified the CrmD gene lacking its
endogenous signal peptide (residues 21–320). Upon restriction,
CrmD was cloned into pAL7 (61), a modified pFastBac1 vec-
tor, in-frame with an N-terminal honeybee melittin signal
peptide and a C-terminal V5-His6 tag. The resulting plasmid
was termed pSP3. Similarly, the coding sequence for three
truncated CrmD proteins, SECRET163 (residues 163–320),
SECRET181 (residues 181–320), and CRD-CrmD (residues
21–162) were extracted from pSP3 by PCR using the primers
CrmD36 (5-gcgggatcctttaacagcatagatgtagaaattaatatgtatcc-
3) and CrmD33, CrmD31 (5-cgcggatccgaattcaattcgag-
tatataggaagcagcagtac-3) and CrmD33, and CrmD34 and
CrmD87 (5-gcgctcgaggcacatattacatctcctttagatg-3), respectively,
and cloned into pAL7 as described above. The resulting plasmids
were termed pSP4, pSP5, and pSP6, respectively.
The CrmD point mutants were generated using the
QuikChange II site-directed mutagenesis kit (Agilent Technolo-
gies, Santa Clara, CA). For this, pSP3 was used as a template in
PCRs using the corresponding primer pair for each mutant (Table
S1). Similarly, the etanercept A127E, L128F, and A127E/L128F
mutants were generated using the primer pairs RM6mut1F (5-
ggctggtactgcgagctgagcaagcag-3) and RM6mut1R (5-ctgcttgct-
cagctcgcagtaccagcc-3), RM6mut2F (5-gctggtactgcgcgttcagca-
agcaggaggg-3) and RM6mut2R (5-ccctcctgcttgctgaacgcgcagtacc-
agc-3), and RM6mut3F (5-cggctggtactgcgagttcagcaagcaggaggg-
3) and RM6mut3R (5-ccctcctgcttgctgaactcgcagtaccagccg-3),
respectively, and pRM6 as a template. pRM6 is a pFastBac1-based
plasmid containing the WT form of etanercept, consisting of the
ligand-binding domain of human TNFR2 fused to the Fc portion
of a human IgG (12). Mutagenesis was confirmed by sequencing.
The plasmids described above were used to generate recom-
binant baculoviruses using the Bac-to-Bac system (Life Tech-
nologies) following the manufacturer’s instructions. Subse-
quently, viral stocks were amplified by infecting adherent Hi5
cells at low multiplicity of infection (0.1– 0.01 pfu/cell).
Protein expression and purification
Hi5 suspension cells were infected with the corresponding
recombinant baculovirus at high multiplicity of infection (2
pfu/cell). Supernatants were harvested 3 days after infection,
clarified at 6,000  g for 40 min, and then concentrated to 2.5
ml in a Stirred Ultrafiltration Cell 8200 (Millipore). The con-
centrate was desalted, and buffer was exchanged to 0.1 M phos-
phate buffer containing 300 mM NaCl and 10 mM imidazole
using PD-10 desalting columns (GE Healthcare). His-tagged
CrmD proteins were purified by metal chelate affinity chroma-
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tography using nickel-nitrilotriacetic acid columns (Qiagen,
Germantown, MD). Etanercept proteins were purified using
protein A– coupled Sepharose columns (Sigma). Protein-con-
taining fractions were pooled, concentrated, and dialyzed in
PBS. Final protein concentration was calculated by gel
densitometry.
Cytotoxicity assays
The ability of CrmD, etanercept, and their mutants to inhibit
TNFSF ligands was tested by cytotoxicity assays on L929 cells as
described previously (12). Briefly, 20 ng/ml hTNF, mTNF, and
hLT were incubated for 1 h at 37 °C in the presence of increas-
ing amounts of recombinant protein. Due to its low specific
activity, mLT was used at 780 ng/ml. Subsequently, the
cytokine–protein mixtures were added to L929 cells seeded at
12,000 cells/well in 96-well plates in the presence of 4 g/ml
actinomycin D (Sigma). Cell viability was assessed after 18 h
using a Cell Titer Aqueous One Solution kit (Promega, Madi-
son,WI)followingthemanufacturer’sinstructions,andtheabsor-
bance at 490 nm (A490) was determined in a Sunrise microplate
reader (Tecan, Mannedorf, Switzerland). The A490 of all sam-
ples was normalized with the A490 of cells incubated only with
the cytokine (0% viability). Cell viability for each sample was
calculated in reference to the A490 obtained in wells where cells
were incubated without cytokine (“media”; 100% viability).
Chemotaxis assay
MOLT-4 cells chemotaxis assays were performed using
96-well ChemoTx plates of 3-m pore size (Neuro Probe,
Gaithersburg, MD). Before the experiment, cells were washed
and resuspended at 10  106 cells/ml in 0.1% FCS in RPMI 1640
medium. Mouse Ccl25 (R&D Systems) at 70 nM was incubated
with increasing molar ratios of recombinant protein at 37 °C for
30 min in the bottom wells. Subsequently, 2.5  105 cells were
placed on the top filter, and cell migration was allowed for 4 h at
37 °C. Afterward, the filter was flushed with PBS to remove
nonmigrated cells, and migration to the lower wells was deter-
mined as the A490 using a Cell Titter Aqueous One Solution kit
(Promega). Cell migration was calculated in reference to the
maximal migration obtained when the cells were incubated
with the chemokine alone (100% cell migration).
SPR assays
The ligand-binding properties of recombinant proteins were
characterized by SPR using a Biacore X biosensor (GE Health-
care). For binding assays, recombinant proteins were immobi-
lized through their amine groups on CM4 chips at high density
(1,000 –2,000 response units). One flow cell of the chip was
treated with buffer alone during immobilization to be used as a
reference. TNFSF cytokines and chemokines were injected at
100 nM in HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3
mM EDTA, 0.005% surfactant P20) (GE Healthcare) at 10
l/min for 3 min followed by a 2-min dissociation. The chip
surface was regenerated between injections with 10 mM glycine
HCl, pH 2.0.
For determination of kinetic affinity constants, recombinant
proteins were immobilized on CM4 chips at low density (500
response units). Increasing concentrations of TNFSF cytokines
and chemokines were injected in HBS-EP buffer at 30 l/min
for 2 min, and a 5-min dissociation was recorded. A 0.1–1000
nM concentration range of analyte was used. Between analyte
injections, the chip surface was regenerated with 10 mM glycine
HCl, pH 2.0. Kinetic data were globally fitted to a 1:1 Langmuir
model using BIAevaluation 3.2 software. Bulk refractive index
changes were removed by subtracting the responses recorded
in the reference flow cell, and the response of a buffer injection
was subtracted from all sensorgrams to remove systematic arti-
facts. To compare the binding affinity constants of CrmD trun-
cated mutants, mean  S.D. KD of 10 fittings from two inde-
pendent experiments was calculated. To determine the kinetic
affinity constants of CrmD point mutants, the average KD of 10
fittings containing sensorgrams for at least six different analyte
concentrations from at least two independent experiments was
calculated. The fitting providing the closest KD to the average
KD was chosen to represent the kinetic affinity constants of
each interaction.
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